HIVEC-II

Title: A phase II, open label, multicentre, randomised controlled trial comparing hyperthermia plus mitomycin to mitomycin alone, in patients with intermediate risk non-muscle invasive bladder cancer
Disease site: Bladder cancer
Status: Follow up

Trial Design: Open-label, multi-centre, randomised controlled trial comparing hyperthermia plus mitomycin (HM) to mitomycin (MM) in patients with new or recurrence of intermediate-risk non-muscle invasive bladder cancer. Standard adjuvant MM is defined as an immediate post-operative single instillation of MM followed by 6 weekly instillations of MM. The primary outcome measures will be disease-free survival at 24 months.  Secondary outcome measures will include recurrence, overall and disease-specific survival in all patients, and recurrence-free survival in patients with papillary disease. The safety and tolerability of HIVEC will be assessed and compared to MM.  The effect on Quality of Life will be assessed in all patients.

Trial details

Chief Investigator: Prof J. Kelly
Trial contact: bci-hivec-ii@qmul.ac.uk
ISRCTN: 23639415
Sponsor: Queen Mary University of London
Participating countries: UK
Source of funding: Combat Medical (funding and study drug)

Patient friendly information

Cancer Research UK website A trial of chemotherapy and hyperthermia for early bladder cancer (HIVEC II)

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.